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Summary 
Background Cerebral malaria, a disorder characterised by coma, parasitaemia, and no other evident cause of coma, is 
challenging to diagnose deﬁ nitively in endemic regions that have high rates of asymptomatic parasitaemia and limited 
neurodiagnostic facilities. A recently described malaria retinopathy improves diagnostic speciﬁ city. We aimed to 
establish whether retinopathy-positive cerebral malaria is a risk factor for epilepsy or other neurodisabilities.
Methods Between 2005 and 2007, we did a prospective cohort study of survivors of cerebral malaria with malaria 
retinopathy in Blantyre, Malawi. Children with cerebral malaria were identiﬁ ed at the time of their index admission and 
age-matched to concurrently admitted children without coma or nervous system infection. Initially matching of cases to 
controls was 1:1 but, in 2006, enrolment criteria for cerebral malaria survivors were revised to limit inclusion to children 
with cerebral malaria and retinopathy on the basis of indirect ophthalmoscopic examination; matching was then 
changed to 1:2 and the revised inclusion criteria were applied retrospectively for children enrolled previously. Clinical 
assessments at discharge and standardised nurse-led follow-up every 3 months thereafter were done to identify children 
with new seizure disorders or other neurodisabilities. A Kaplan-Meier survival analysis was done for incident epilepsy.
Findings 132 children with retinopathy-positive cerebral malaria and 264 age-matched, non-comatose controls were 
followed up for a median of 495 days (IQR 195–819). 12 of 132 cerebral malaria survivors developed epilepsy versus 
none of 264 controls (odds ratio [OR] undeﬁ ned; p<0·0001). 28 of 121 cerebral malaria survivors developed new 
neurodisabilities, characterised by gross motor, sensory, or language deﬁ cits, compared with two of 253 controls 
(OR 37·8, 95% CI 8·8–161·8; p<0·0001). The risk factors for epilepsy in children with cerebral malaria were a higher 
maximum temperature (39·4°C [SD 1·2] vs 38·5°C [1·1]; p=0·01) and acute seizures (11/12 vs 76/120; OR 6·37, 95% CI 
1·02–141·2), and male sex was a risk factor for new neurodisabilities (20/28 vs 38/93; OR 3·62, 1·44–9·06). 
Interpretation Almost a third of retinopathy-positive cerebral malaria survivors developed epilepsy or other 
neurobehavioural sequelae. Neuroprotective clinical trials aimed at managing hyperpyrexia and optimising seizure 
control are warranted. 
Funding US National Institutes of Health and Wellcome Trust.
Introduction 
Cerebral malaria, a disorder characterised by coma, 
parasitaemia, and no other evident cause of coma,1 aﬀ ects 
about half a million children every year, primarily in 
sub-Saharan Africa.2 The case-fatality rate of cerebral 
malaria is estimated to be about 15%, with risk factors for 
death being deeper coma or coma of longer duration, 
younger age, seizures, hypoglycaemia, and hyper-
parasitaemia.3,4 Neurological sequelae, including cortical 
blindness, gross motor deﬁ cits, ataxia, language 
regression, epilepsy, and behavioural abnormalities, have 
been reported at discharge in 10–20% of survivors, with 
follow-up assessments suggesting that gross deﬁ cits 
usually resolve within a few weeks of recovery.4–9 
Most previous studies of neurological sequelae related 
to cerebral malaria have been limited by poor retention 
rates, short duration of follow-up, and assessments that 
were stopped when the results of neurological 
examinations were normal. Delayed cerebral malaria 
sequelae, such as epilepsy, have been reported in studies 
designed to identify them: a retrospective cohort study 
in Kenya10 reported that 14 (9·2%) of 152 survivors 
developed epilepsy compared with four (2·2%) of 179 in 
the control group, and in Mali, a prospective study11 
identiﬁ ed epilepsy in ﬁ ve (4·9%) of 101 survivors of 
cerebral malaria compared with one (0·5%) of 
222 controls. Cognitive impairment has also been 
reported after recovery from cerebral malaria.12–14 
However, these longer-term ﬁ ndings had diagnostic 
limitations. Cerebral malaria is challenging to diagnose 
deﬁ nitively in endemic regions in which there are high 
rates of asymptomatic parasitaemia and limited 
neurodiagnostic resources. Autopsy studies show that 
about 23% of children meeting the standard clinical 
case deﬁ nition of cerebral malaria have a non-malarial 
cause for coma and lack CNS sequestration of 
parasitised erythrocytes.15 Previous outcome studies, 
which are reviewed systematically in the webappendix, 
have relied upon the standard clinical case deﬁ nition of 
cerebral malaria.
See Online for webappendix
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Malaria retinopathy, recently described in children, 
enhances the potential for diagnosis with 95% sensitivity 
and 90% speciﬁ city as compared with autopsy ﬁ ndings 
as the gold standard.16 Children meeting the standard 
clinical case deﬁ nition of cerebral malaria who lack 
malaria retinopathy have a higher prevalence of 
pre-existing neurodisabilities and of family history of 
epilepsy compared with matched controls, which 
suggests that children with retinopathy-negative cerebral 
malaria have a pre-existing propensity toward adverse 
neurological symptoms and outcomes.17 Adverse 
neurological outcomes previously reported in cerebral 
malaria might have included children with neurological 
abnormalities preceding their malarial infection, and 
these pre-existing abnormalities might have contributed 
to the malaria-associated coma.
To establish whether retinopathy-positive cerebral 
malaria is a risk factor for epilepsy or other neurodisability 
and, if so, whether there are modiﬁ able risk factors that 
oﬀ er potential opportunities for early intervention, we 
did a prospective cohort study of children with 
retinopathy-positive cerebral malaria. Follow-up assess-
ments were designed to identify interim seizures and 
new neurodisabilities. 
Methods 
Participants 
We did a prospective cohort study of cerebral malaria 
survivors who were admitted to the paediatric research 
ward of Queen Elizabeth Central Hospital (QECH), 
Blantyre, Malawi, during the malaria season (January–
June) from 2005 to 2007 and who resided within the 
catchment area (within 1·5 h travel time from QECH by 
four-wheeled drive vehicle, with distances varying due to 
road conditions). Because QECH is in a region endemic 
for malaria, which is one of the commonest causes of 
illness in Malawian children, all comatose children 
admitted to QECH have a thick blood ﬁ lm reviewed to 
screen for Plasmodium falciparum. In Blantyre, about 
83% of caregivers of children younger than 5 years cited 
fever and malaria as the impetus for seeking medical 
care in 2006–07.18 The group with cerebral malaria 
originally included all surviving children for whom 
consent was obtained and who met the standard clinical 
case deﬁ nition of cerebral malaria: Blantyre coma score 
(BCS)19 less than or equal to 2, P falciparum parasitaemia, 
and no other evident cause of coma. We used the Epilepsy 
Screening Questionnaire to exclude children with a 
history of previous unprovoked seizures. This question-
naire has been previously used with 79·3% sensitivity 
and 92·9% speciﬁ city for detection of epilepsy.20 We 
applied the Ten Questions screen21,22 to identify children 
with preadmission neurodisabilities. This screen detects 
neurodevelopmental disabilities in children and has been 
shown to be valid in children as young as 2 years in 
similar environments with good reliability (κ=0·67) 
and 85% sensitivity. Children with pre-existing 
neurodisabilities were eligible for enrolment and were 
followed up for the outcome of epilepsy, but were not 
included in analyses of subsequent neurodisabilities. 
There was no strict age limit and any comatose child who 
could ﬁ t in the paediatric cots on the ward was eligible 
for admission. 
Throughout recruitment, all patients with cerebral 
malaria had an ophthalmological assessment on 
admission. In 2006–07, enrolment criteria for cerebral 
malaria survivors were revised to limit case inclusion to 
children with retinopathy-positive cerebral malaria on 
the basis of indirect ophthalmoscopic examination 
through a dilated pupil by a qualiﬁ ed ophthalmologist. 
Patients without malaria retinopathy and a small number 
of children who did not have a retinal examination while 
comatose were excluded from this analysis. These 
patients have been described elsewhere.17 The revised 
inclusion criteria used from 2006 onward were applied 
retrospectively to the children enrolled in 2005.
The control group consisted of the ﬁ rst eligible child 
who was admitted to the general paediatric service after 
each case was enrolled and who was age-matched to 
within 6 months. Inclusion criteria for age-matched 
controls were residence within 1·5 h travel from QECH 
by four-wheeled drive vehicle, a normal level of 
consciousness, and no history of unprovoked seizures 
before the index admission. Children with a brief febrile 
seizure before admission who were conscious on 
admission were eligible. Children with P falciparum 
parasitaemia were eligible as controls, although the 
presence of parasitaemia was not a requirement and not 
all control children were tested for malaria. The 
comparison group was also screened acutely with the 
Epilepsy Screening Questionnaire and the Ten Questions 
screen to identify children with a history of previous 
unprovoked seizures and those with pre-existing 
neurodisabilities. The ﬁ ndings from these questionnaires 
were used in the unexposed comparison group exactly as 
they were in the exposed group. Children with a history 
of unprovoked seizures were excluded from enrolment. 
Those with a history of neurodisability were eligible for 
inclusion but were excluded from analyses of the 
neurodisability outcome. 
Our study was approved by the University of Malawi 
College of Medicine Research Ethics Committee and 
Michigan State University Biomedical Institutional 
Review Board. Signed informed consent was provided by 
the parents or guardians of the study participants.
Procedures 
We planned to recruit 225 cerebral malaria survivors 
matched 1:1 with unexposed controls. The addition of 
malaria retinopathy as an inclusion criterion in 2006 
reduced the number of qualifying participants. 
Therefore, matching was increased to 1:2, to increase 
precision in estimates of diﬀ erences between groups. 
Recruitment was continued through the 2007 malaria 
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season with the goal of enrolling as many children as 
possible and assessments continued through to 
December, 2009, to allow at least 18 months of follow-up 
for the last children enrolled. Therefore, children 
enrolled earlier in the cohort were followed up for longer 
than children enrolled later.
For both cases and controls, several clinical 
characteristics, including established risk factors for 
seizures and epilepsy, were documented at enrolment. 
A research nurse interviewed caregivers (usually the 
mother) with the Epilepsy Screening Questionnaire 
and the Ten Questions screen, and recorded 
demographic data including age and sex. Potential pre-
existing risk factors for epilepsy and adverse neurological 
outcomes were assessed including family history of 
epilepsy,23,24 questions on delayed cry (was the child’s 
birth problematic? did the child cry immediately after 
birth?),25 and birthweight from the health passport or 
under-5s card, if available.26 Family history was 
established with the Epilepsy Screening Questionnaire. 
If a parent or sibling screened positive, further follow-
up questions were asked to conﬁ rm that this was a 
primary relative related to the patient biologically and 
to clarify the age of the person at the time they 
experienced the seizures. If the relative identiﬁ ed was 
not a primary relative, had experienced only a single 
seizure, or had seizures in association with childhood 
fever or illness, the child was not classiﬁ ed as having a 
family history of epilepsy. We also noted any previous 
history of severe malaria, deﬁ ned as malaria that needed 
hospital admission. 
On admission to the paediatric research ward, we 
recorded details of the general and neurological 
examination. We did not commence enrolment in the 
long-term follow-up study until survival was probable, 
usually on day 2 or 3 of the admission after acute data 
had already been collected. Laboratory investigations 
included full blood count, packed cell volume, lactate and 
glucose concentration, and thick and thin blood smears 
(with Field’s stains) to identify the species and quantify 
malaria parasitaemia. Temperature and coma score were 
recorded serially. Seizures related to cerebral malaria 
were recorded on the basis of clinical identiﬁ cation as 
well as electroencephalogram (EEG) ﬁ ndings. 
For patients with cerebral malaria, digital EEGs were 
obtained on the day of admission and daily thereafter until 
recovery from coma. EEGs were recorded with a BioLogic 
Ceegraph digital machine (Natus Medical Incorporated, 
San Carlos, CA USA) with a modiﬁ ed 10–20 system and 
met the American Electroencephalography Society 
guidelines for EEG.27 EEGs were interpreted acutely for 
clinical purposes and later categorised with the modiﬁ ed 
Synek classiﬁ cation system28,29 (GLB). 36 (25%) of 146 EEGs 
had a second interpretation and modiﬁ ed Synek score 
assigned by an epileptologist (PWK) masked to everything 
except the BCS and patient age, to assess the validity of the 
initial acute interpretations and Synek scoring.
At discharge, neurological assessment was completed 
by the attending physician (a paediatrician or internist), 
and for all study participants discharge diagnoses and 
body-mass index were recorded. Children were then 
reviewed by a study nurse at 1 month after discharge and 
then every 3 months until the study was completed. At 
follow-up assessments, which were done at the hospital 
or via home-based visits led by nurses, study nurses 
repeated the Epilepsy Screening Questionnaire and the 
Ten Questions screen to identify any interim seizures or 
newly evident neurodisabilities. All children who were 
discharged with neurological sequelae, had interim 
seizures, or screened positive on the Ten Questions 
screen during follow-up were assessed by a neurologist 
(GLB) to characterise their seizure disorder or the nature 
of the neurological disability. Any additional concerns or 
issues from either the research nurses or the parents 
also triggered a physician-level review of the child. The 
examining neurologist and study nurses were all 
involved in the acute care of the study participants and 
thus exposure status was not masked. Children who 
initially screened negative on the Ten Questions screen 
and who later exhibited motor, sensory, or language 
impairment were deemed to have a new neurodisability. 
Interim seizures that happened during follow-up were 
deemed provoked seizures if health care was sought and 
a fever was documented, the parent reported a tactile 
temperature or measured a fever around the time of the 
seizure, the parent reported an illness preceding the 
seizure, or parasitaemia was recorded on the day of the 
seizure even in the absence of acute fever. More than 
one unprovoked seizure during follow-up was needed 
for a child to meet the diagnostic criteria for epilepsy. If 
a child’s family moved outside of our deﬁ ned catchment 
area, the child was no longer followed up unless the 
parents brought them to the paediatric research ward for 
their quarterly assessments.
Several children without seizures or neurodisability 
were referred for physician-level assessment because of 
parental concerns about new behavioural problems. 
Assessment of these children by a neurologist (GLB) in 
two diﬀ erent settings (at home and school or at their 
parental home and at a relative’s home) were done and all 
met Diagnostic and Statistical Manual of Mental Disorders 
(4th edn) criteria for hyperactive-impulsive attention-
deﬁ cit hyperactive disorder (ADHD).30 Although ADHD 
was not a prespeciﬁ ed outcome in our study, we include 
an analysis of this disruptive behavioural disorder group.
At the time of enrolment, neither acute neuroimaging 
nor ventilatory support was available on the QECH 
paediatric research ward. All children with cerebral 
malaria received treatment for acute severe malaria 
according to national guidelines that included blood 
transfusions if indicated, intravenous quinine, and 
benzodiazepines or paraldehyde for acute symptomatic 
seizures. For refractory seizures, additional antiepileptic 
drugs, usually phenobarbital, were given.
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Statistical analysis 
Recruitment of 225 cerebral malaria survivors matched 1:1 
with unexposed controls would have provided 87% power 
to detect an 8% diﬀ erence in epilepsy development. Data 
were originally recorded on paper forms with subsequent 
double data entry into Microsoft Oﬃ  ce Excel 97–2003 
software. This was then imported into EPI INFO 
(version 3.5) for analysis. Calculations of geometric means 
for parasitaemia were completed using Dimensions 
Research online software.31 
The admission characteristics of retinopathy-positive 
cerebral malaria survivors and controls were compared 
with t tests and odds ratios (ORs). Owing to the revised 
inclusion criteria in 2006–07 for cerebral malaria cases, 
and to use data obtained from all controls, we did an 
unmatched analysis comparing the group of cerebral 
malaria survivors versus controls. We assessed the ORs 
of incident epilepsy, new neurodisability, disruptive 
behavioural disorders, any adverse neurological outcome, 
and death. We did a Kaplan-Meier survival analysis for 
incident epilepsy, our primary outcome of interest. Any 
children lost to follow-up were censored from the data on 
the day after their last follow-up. To identify potential risk 
factors for adverse neurological outcomes in cerebral 
malaria survivors, we also assessed acute clinical 
characteristics associated with adverse neurological 
outcomes (epilepsy, neurodisability, disruptive behavioural 
disorder, or the pooled outcome of any adverse 
neurological sequelae) with the t test or OR with 95% CIs. 
For any χ2 assessment with less than ﬁ ve items of data in 
a cell, Fisher’s exact test was used. For t-test comparisons, 
Bartlett’s test for population variance was assessed and 
where indicated (ie, if there was signiﬁ cant population 
variance [p<0·05]) the Kruskal-Wallis (non-parametric) 
test was used. Because of the variance from our initial 
recruitment and analysis plan, we also did a sensitivity 
analysis of the risk of each adverse neurological outcome 
with matched pairs that included the ﬁ rst matched control 
selected for each case. 
Role of the funding source 
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results 
Figure 1 shows cohort recruitment. 132 children with 
retinopathy-positive malaria and 264 controls were recruited 
and followed up for a mean of 544 days (median 495; IQR 
195–819). The most common discharge diagnoses in the 
control group were malaria, pneumonia, and gastroenteritis, 
accounting for 190 controls. Children in the control group 
who had malaria were admitted because of a febrile seizure 
at home, anaemia, or possible anaemia—children with 
uncomplicated malaria are generally not admitted.
The duration of follow-up from recruitment to an 
adverse outcome or attrition did not diﬀ er signiﬁ cantly 
between cases and controls (mean 534 days [SD 453] vs 
446 [374]; p=0·13). However, follow-up every 3 months 
was maintained through to December, 2009, in 101 (77%) 
of 132 cases and 172 (65%) of 264 controls (p=0·02). 
Attrition was due to death in six cases (5%) and three 
controls (1%), to withdrawal in seven cases (6%) and 
Figure 1: Cohort recruitment
82 traditionally deﬁned cerebral
malaria survivors
132 retinopathy-positive
survivors followed up
101 completed follow-up
58 traditionally deﬁned
survivors added in
year 2
35 retinopathy-positive
survivors added in
year 3
35 without retinopathy 
excluded
8 without eye 
   examinations excluded
31 lost before 
December, 2009
6 deaths
7 withdrawals
18 moved
82 controls to match cases 1:1
264 controls followed up
172 completed follow-up
116 controls added in 
year 2 to match 
cases 1:2
66 controls added in
year 3 to match
cases 1:2
92 lost before
December, 2009
3 deaths
12 withdrawals
77 moved
Cerebral malaria 
survivors (n=132)
Controls
(n=264)
Odds ratio (95% CI)
Male 65 (49%) 148 (56%) 0·76 (0·50–1·16)
Age (months) 42·3 (25·1) 42·8 (27·5) 1·00 (0·99–1·01)
Body-mass index (kg/m²) 15·6 (2·9) 15·6 (3·0) 1·00 (0·93–1·07)
Axillary temperature on admission (°C) 38·3 (1·3) 38·4 (1·2) 0·94 (0·79–1·11)
Birthweight (kg)* 3·2 (0·6) 3·2 (0·7) 1·63 (0·55–4·78)
Problem birth or delayed cry 8 (6%) 13 (5%) 1·25 (0·50–3·08)
Pre-existing neurodisability† 11 (8%) 11 (4%) 2·09 (0·88–4·96)
History of severe malaria‡ 6 (5%) 12 (5%) 1·00 (0·37–2·73)
Family history of epilepsy 10 (8%) 12 (5%) 1·72 (0·72–4·09)
Data are n (%), odds ratio (95% CI), or mean (SD). *62 cerebral malaria survivors and 173 controls. †Established 
through the Ten Questions screen. ‡Deﬁ ned as a malaria infection that needed hospital admission.
Table 1: Characteristics at admission
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12 controls (5%), and to family relocation outside of the 
tracking area in 18 cases (14%) and 77 controls (29%). 
We provided ongoing medical care to the 42 children 
who had experienced adverse neurological outcomes. 
Among these children, 14 had families who relocated 
outside of the tracking area during this study, but parents 
for all 14 of these children continued to bring them in for 
assessments. Had these children been withdrawn from 
the study at the time of the relocation, the rate of study 
completion in the cerebral malaria survivors would have 
been 53% (70 of 132). To our knowledge, there were no 
children in the control group whose parents continued to 
bring them for quarterly assessments after family 
relocation outside the tracking area. When we compared 
the age, sex, enrolment date, and outcome of children 
who completed follow-up through to December, 2009, 
with those of children who did not complete follow-up, 
more recent enrolment and having an adverse 
neurological outcome were both associated with higher 
completion rates. There was no diﬀ erence in the 
proportion of cases versus controls who continued follow-
up for the full duration of the study once the children 
with adverse neurological outcomes were excluded from 
the comparison (60 [67%] of 90 cases vs 170 [65%] of 261 
controls; p=0·48). 
Table 1 shows the characteristics of the cerebral malaria 
cases and controls at admission. Inter-rater agreement in 
ratings from the two independent EEG readers (GLB and 
PWK) for the eight-category modiﬁ ed Synek classiﬁ cation 
system was 0·88 (95% CI 0·78–0·98), with no disagreement 
on electrographic seizure identiﬁ cation. Nine (19%) of 
48 children who had no witnessed seizures before 
admission and no clinical evidence of seizure on admission 
had seizure activity evident on their admission EEG. 
Table 2 shows outcomes in cerebral malaria survivors 
versus unexposed controls. Cerebral malaria survivors 
were at raised risk of epilepsy, new neurodisabilities, and 
disruptive behavioural disorders. Overall, 42 cerebral 
malaria survivors (32%) had at least one adverse 
neurological outcome. The case-fatality rate during 
follow-up was greater for cerebral malaria survivors than 
for controls (table 2). These ﬁ ndings remained signiﬁ cant 
in the matched sensitivity analysis (data not shown). 
Figure 2 shows the distribution and comorbidity of 
neurological sequelae among the cerebral malaria 
survivors. Multiple adverse neurological outcomes 
happened sequentially, with motor, sensory, or language 
deﬁ cits being evident initially (median 111 days after 
discharge, IQR 23–228), then disruptive behavioural 
disorders (150 days, 83–228), and lastly epilepsy (309 days, 
111–524). The time to adverse outcome is for all patients, 
not just those with more than one event.
Figure 3 shows the Kaplan-Meier survival analysis for 
incident epilepsy in cerebral malaria survivors versus 
controls. Epilepsy in cerebral malaria survivors was 
characterised by localisation-related epilepsy with the 
epileptic focus (established by seizure semiology, EEG, 
and neuroimaging) corresponding to focal brain regions 
involved with status epilepticus or repeated seizures 
during the acute cerebral malaria infection.32 The children 
who developed epilepsy all needed treatment for recurrent 
seizures, many had refractory seizures that needed more 
than one antiepileptic drug, and two died in status 
epilepticus. Table 3 provides further details of the epilepsy 
syndrome after cerebral malaria.
At discharge, the attending physician identiﬁ ed 
hemiparesis or monoparesis in seven of 132 patients with 
cerebral malaria, hypotonia in four, gait ataxia in two, 
speech regression in four, and choreiform movements in 
one. These neurological deﬁ cits at discharge are consistent 
with previous studies of paediatric cerebral malaria sequelae 
at discharge from QECH.33 An additional 16 children had 
new neurodisabilities identiﬁ ed during follow-up. All 
42 children with adverse neurological outcomes were 
examined by a neurologist: 12 had spastic quadriparesis 
usually accompanied by language regression or cortical 
blindness; 12 had isolated language regression or delayed 
speech; six had motor and language regression or delay; 
ﬁ ve had hemiparesis; four had monoparesis; and three had 
isolated ataxia. Outcomes were not mutually exclusive. 
Table 4 lists potential risk factors for adverse neurological 
outcomes of cerebral malaria survivors. A higher maximum 
Cerebral malaria survivors Controls Odds ratio (95% CI)
Epilepsy 12/132 (9%) 0/264 (0%) Undeﬁ ned (4·8–15·3 
[cases]; 0–1·4 [controls]) 
Disruptive behavioural disorder 14/132 (10·6%) 1/264 (0·4%) 31·2 (4·1–240·1)
New neurodisabilities* 28/121 (23·1%) 2/253 (0·8%) 37·8 (8·8–161·8)
Death 6/132 (4·5%) 3/264 (1·1%) 4·1 (1·02–16·8)
Outcomes are not mutually exclusive. Data are n/N (%) or OR (95% CI). *Excludes children with a history of 
neurodisability at the time of presentation.
Table 2: Outcomes in cerebral malaria survivors and controls
Figure 2: Distribution of comorbid neurological sequelae after cerebral 
malaria
Epilepsy n=3 Neurodisability n=21
n=4 n=2
n=4
Disruptive behavioural
disorder
n=7
n=1
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temperature was associated with epilepsy and disruptive 
behavioural disorders, a BCS on admission of 0 or 1 was 
associated with disruptive behavioural disorders, seizures 
during admission were a risk factor for epilepsy, and male 
sex was a risk for subsequent neurodisabilities. 
Discussion 
Our prospective study describes neurological outcomes 
for a population of well characterised paediatric cerebral 
malaria survivors. Our acute clinical data provide 
information on the clinical characteristics predictive of 
brain injury in survivors (panel). Acute and serial EEGs 
were especially important for identifying subclinical 
seizures, and inclusion of cerebral malaria retinopathy 
in the diagnostic criteria improved the certainty of 
diagnosis. Previous cerebral malaria outcomes studies 
did not include retinal assessments and thus probably 
included children with pre-existing neurological injuries, 
a predisposition to adverse neurological outcomes, or a 
non-malarial cause of coma. The population studied and 
their outcomes are probably representative of children 
Figure 3: Kaplan-Meier curve for epilepsy outcome
Statistical signiﬁ cance is by log-rank test.
Number at risk
Control
Case
0
264
132
500
110
81
1000
22
30
1500
6
8
Follow-up (days)
0
0·2
0·4
0·6
0·8
1·0
Su
rv
iv
al
 w
ith
ou
t e
pi
le
ps
y
Control
Case
p<0·0001
Age at index 
admission 
(months)
Seizure types Seizure frequency Treatment Clinical course
Child 1 12 Focal motor with secondary 
generalisation
Two to three per month on 
treatment
Phenobarbital Mother concerned that two antiepileptic drugs caused worsening in 
already compromised gait and unwilling to use second antiepileptic 
drug
Child 2 32 Generalised tonic clonic Seizure free on treatment Carbamazepine Poor response to phenobarbital, which caused behavioural 
problems and aggression
Child 3 50 Generalised tonic clonic One to two per month without 
treatment
None Tried phenobarbital, then carbamazepine. Both decreased seizure 
frequency but were associated with aggressive behaviours so 
parents declined further treatment
Child 4 10 Right upper-extremity focal motor 
with or without secondary 
generalised tonic clonic
Seizure free on treatment Phenobarbital Mother reported breakthrough seizures whenever they ran out of 
medication for more than 1 week
Child 5 23 Generalised tonic clonic Two to three per week oﬀ  
treatment
Phenobarbital, then 
carbamazepine, 
then both
Decreased seizure frequency to about one per week and decreased 
duration to minutes
Child 6 11 Focal motor and generalised tonic 
clonic
Multifocal and generalised tonic 
clonic daily
Phenobarbital with 
carbamazepine
Spastic quadriparesis, non-verbal, frequent seizures. Died at home 
of status epilepticus 2 weeks after family ran out of phenobarbital
Child 7 37 Generalised tonic clonic One per month on average; more 
with any febrile illness
Phenobarbital Limited follow-up details available
Child 8 28 Generalised tonic clonic and 
possible myoclonic
Two to three per week (brief and in 
clusters)
Phenobarbital with 
carbamazepine
Spastic quadriparesis, non-verbal. Eﬀ ect on quality of life unclear
Child 9 38 Multifocal with or without 
secondary generalised tonic clonic
Right focal motor initially Phenobarbital Controlled on phenobarbital. Last visit, mother requested that the 
child be weaned oﬀ  antiepileptic drugs
Child 10 48 Complex partial seizures with 
secondary generalisation and 
post-ictal psychosis and 
aggression 
One to two per month but many 
more with any febrile illness
Phenobarbital, 
then 
carbamazepine
Shorter duration of seizures when on carbamazepine. One 
admission to hospital other than QECH with status epilepticus 
associated with a fever from respiratory illness
Child 11 47 Generalised tonic clonic Unclear—died before pattern could 
be fully assessed
Phenobarbital Developed gastroenteritis and was treated at home despite severe 
dehydration. On day 4 of illness, developed status epilepticus and 
died on the way to hospital
Child 12 42 Generalised tonic clonic Less than one per month, although 
clearly recurrent and more 
frequent with any febrile illness
Phenobarbital Well controlled and mother interested in weaning from 
antiepileptic drugs
QECH=Queen Elizabeth Central Hospital.
Table 3: Clinical characteristics of epilepsy after cerebral malaria
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with cerebral malaria who receive care in tertiary care 
settings within sub-Saharan Africa, but might diﬀ er 
from children with cerebral malaria treated within more 
community-based settings, where disease might be less 
severe but care might be less assiduous.
Several limitations of our study deserve a mention. 
Overall, cases were followed up longer than controls. A 
longer follow-up and higher retention rate among cases 
might have caused us to overestimate the eﬀ ects of 
cerebral malaria. However, the duration of follow-up 
from recruitment to initial adverse outcome or attrition 
did not diﬀ er signiﬁ cantly between cases and unexposed 
controls, and when children with adverse neurological 
outcomes were excluded from the comparison, the 
proportion of cases versus controls who continued follow-
up for the full duration of the study did not diﬀ er. These 
ﬁ ndings suggest that the additional medical services 
provided to children with adverse neurological outcomes 
represented an incentive for ongoing follow-up visits, 
and confounding is probably limited. 
We used the Epilepsy Screening Questionnaire to 
exclude children with a history of unprovoked seizures; 
however, it has not been validated for use in Malawian 
children. We used the Ten Questions screen to assess 
neurodisabilities. This screen lacks sensitivity in children 
younger than 2 years; 79 children (20%) in our study 
were younger than 2 years at the time of their ﬁ rst 
follow-up. We are not aware of any screening methods 
for identifying neurodisabilities in children younger than 
2 years that have been validated for use by non-physician 
health-care workers in an African setting. Owing to 
age-based matching, extent of use of the Ten Questions 
screen in children younger than 2 years did not diﬀ er for 
cases versus controls and 382 (97%) of 396 children were 
screened at least once after reaching the age of 2 years. 
Before we started our study in 2005, behavioural 
disorders had not been reported as sequelae of cerebral 
malaria and behavioural disorders were not a pre-
speciﬁ ed outcome. Recent retrospective clinic-based 
studies from Mali8 and Uganda9 have reported behavioural 
problems in cerebral malaria survivors, corroborating 
our unexpected ﬁ ndings. Children assessed explicitly for 
behavioural problems in our study were only those 
brought to the attention of the research team by the 
troubled parents. The prevalence of disruptive behavioural 
disorders in Malawian children is not known, but the 
worldwide prevalence of ADHD is estimated to be 5·3%.34 
No culturally validated methods yet exist for diagnosing 
Epilepsy 
(n=12)
Disruptive behavioural disorder 
(n=14)
Neurodisabilities 
(n=28)
Any adverse neurological outcome 
(n=42)
Age (months) 41·3 (28·4) vs 42·4 (24·8); p=0·88 40·3 (28·8) vs 42·5 (24·7); p=0·75 49·3 (25·1) vs 39·9 (22·2); p=0·06 43·9 (23·9) vs 41·6 (25·7); p=0·62
Male 7/12 (58%) vs 58/120 (48%)
OR 1·50 (0·45–4·98)
8/14 (57%) vs 57/118 (48%)
OR 1·43 (0·47–4·37)
20/28 (71%) vs 38/93 (41%)
OR 3·62 (1·44–9·06)*
6/41 (63%) vs 39/91 (43%) 
OR 2·31 (1·08–4·94)
Body-mass index (kg/m²) 17·0 ( 3·23) vs 15·5 ( 2·86); p=0·09 15·8 (3·79) vs 15·6 (2·81); p=0·78 15·8 (2·51) vs 15·3 (2·80); p=0·40 15·8 (2·93) vs 15·5 (2·92); p=0·58
Family history of epilepsy 1/12 (8%) vs 9/120 (8%) 
OR 1·12 (0·13–9·69)
1/14 (7%) vs 9/118 (8%) 
OR 0·93 (0·11–7·95)
4/28 (14%) vs 5/93 (5%) 
OR 2·93 (0·73–11·78)
5/36 (12%) vs 5/91 (6%) 
OR 2·39 (0·65–8·76)
Admission temperature (°C) 38·2 (1·25) vs 38·9 (1·36); p=0·08 38·4 (1·45) vs 38·3 (1·26); p=0·76 38·3 (1·34) vs 38·3 (1·28); p=0·98 38·4 (1·35) vs 38·2 (1·24); p=0·43
Blantyre coma score 
<2 at admission
8/12 (67%) vs 54/120 (45%)
OR 2·44 (0·70–8·56)
11/14 (79%) vs 51/118 (43%)
OR 4·82 (1·28–18·17)*
17/28 (61%) vs 40/93 (43%)
OR 2·04 (0·89–4·96)
29/43 (67%) vs 33/89 (37%) 
OR 3·52 (1·63–7·59)
Haematocrit at admission 
(% packed cell volume 
per μL)
18·2 (5·02) vs 18·2 (5·49); p=0·98 18·4 (4·01) vs 18·2 (5·60); p=0·90 18·8 (7·35) vs 18·0 (4·95); p=0·86 18·6 (6·36) vs 18·0 (4·98); p=0·63
White blood cell count at 
admission (mean count 
per μL)
10 718 (3035) vs 14 010 (11 330); 
p=0·69
10 583 (3910) vs 14 057 (11 342); 
p=0·47
14 426 (6480) vs 13 480 (11 337); 
p=0·07
13 146 (5953) vs 13 935 (12 427); 
p=0·19
Positive blood culture 1/11 (10%) vs 11/114 (9%) 
OR 1·07 (0·12–9·15)
1/12 (8%) vs 11/113 (10%) 
OR 1·19 (0·14–10·08)
3/27 (9%) vs 8/88 (9%) 
OR 0·80 (0·20–3·25)
4/12 (9%) vs 78/113 (10%) 
OR 0·90 (0·25–3·18) 
Parasitaemia (geometric 
mean parasite per μL)
18 138 (371 686) vs 25 388 (180 994); 
p=0·10
21 292 (371 385) vs 10 084 (227 806); 
p=0·09
18 491 (381 325) vs 25 345 (244 726); 
p=0·11
19 593 (395 388) vs 19 821 (250 958); 
p=0·93
Lactate >5 (mg/μL) 7/12 (58%) vs 62/115 (54%)
OR 1·20 (0·36–3·99)
5/13 (39%) vs 64/114 (53%) 
OR 0·49 (0·15–1·58)
16/27 (59%) vs 48/91 (53%)
OR 1·30 (0·54–3·11)
22/40 (55%) vs 47/87 (54%) 
OR 1·54 (0·74–3·24)
Hypoglycaemia† 6/12 (50%) vs 55/120 (46%)
OR 1·39 (0·91–1·13)
6/14 (43%) vs 55/118 (47%)
OR 0·98 (0·88–1·11)
16/28 (53%) vs 42/93 (44%)
OR 1·09 (0·90–1·31)
22/41 (4%) vs 39/91 (43%) 
OR 1·10 (0·87–1·40)
Maximum temperature (°C) 39·4 (1·17) vs 38·5 (1·10); p=0·01* 39·2 (1·00) vs 38·6 (1·13); p=0·04* 38·6 (1·18) vs 38·6 (1·14); p=0·97 38·9 (1·17) vs 38·5 (1·10); p=0·08
Seizures during cerebral 
malaria‡
11/12 (92%) vs 76/120 (63%)
OR 6·37 (1·02–141·20)*
9/14 (64%) vs 78/118 (66%)
OR 0·92 (0·29–2·94)
20/28 (71%) vs 57/93 (61%)
OR 1·58 (0·63–3·96)
30/41 (73%) vs 57/91 (3%) 
OR 1·63 (0·72–3·66)
Time to coma 
resolution (h)
46·6 (37·9) vs 53·4 (39·5); p=0·66 44·7 (22·1) vs 54·0 (40·9); p=0·70 48·3 (29·7) vs 53·9 (41·6); p=0·63 46·4 (25·5) vs 55·2 (43·0); p=0·61
Data are mean (SD), n/N (%), or OR (95% CI), for event versus no event. Outcomes are not mutually exclusive. OR=odds ratio. *Signiﬁ cant ﬁ ndings. †Deﬁ ned as a glucose <2·2 mmol/L. ‡Seizures related to 
cerebral malaria were documented on the basis of clinical identiﬁ cation as well as EEG ﬁ ndings. 
Table 4: Risk factors for adverse neurological outcomes
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ADHD or other disruptive behavioural disorders in 
Malawi. Further studies of behavioural problems after 
cerebral malaria are needed and will require the 
development and validation of appropriate instruments 
for characterising paediatric behavioural problems in 
this population. Longer term and more sophisticated 
assessments of epilepsy and of cognitive and behavioural 
outcomes are also needed. 
Our ﬁ ndings show that retinopathy-positive cerebral 
malaria is a risk factor for several adverse neurological 
outcomes including epilepsy, disruptive behavioural 
disorders, and neurodisabilities characterised by motor, 
sensory, or language deﬁ cits. Most sequelae were delayed 
in presentation and hence were not evident at the time of 
discharge from the hospital after the initial illness. Cerebral 
sequestration of parasites is the hallmark of cerebral 
malaria and the only methods available for conﬁ rming 
CNS sequestration require analysis of brain tissue. As 
such, it is diﬃ  cult to know how representative this 
population of children with retinopathy-positive cerebral 
malaria is of all children with cerebral malaria. If the 
ﬁ ndings of our study are generalisable, then about 135 000 
African children younger than 5 years have neurological 
sequelae due to cerebral malaria-induced brain injury each 
year and cerebral malaria might be one of the more 
common causes of epilepsy in malaria-endemic regions. 
The syndrome of epilepsy after cerebral malaria 
described in our cohort of cerebral malaria survivors is 
primarily localisation-related epilepsy that is often 
associated with other neurodisabilities and refractory to 
treatment with a single drug. Early mortality in two of 
12 children who developed epilepsy suggests that 
retrospective studies might not identify epilepsy that 
results in early deaths.
The ﬁ nding that boys were at greater risk for new 
neurodisability was unexpected and might suggest that 
the Ten Questions screen has some sex-based bias in the 
Malawi population. However, recent epidemiological 
studies have established that boys experience higher 
stroke mortality rates across all paediatric age ranges35 
and also seem to be more susceptible to arterial, neonatal, 
traumatic, and non-traumatic strokes than are girls.36 
Most of the risk factors for adverse neurological 
outcomes after cerebral malaria identiﬁ ed in this study 
are consistent with data from other causes of CNS injury. 
Hyperthermia is a risk factor for adverse outcome in 
stroke and traumatic brain injury,37,38 and secondary 
ADHD has been reported after paediatric traumatic brain 
injury with prolonged coma.39 The relation in our study 
between acute seizures and later epilepsy might suggest 
an underlying causal pathway in which acute seizures 
induce epileptogenesis.40 Alternatively, such acute 
symptomatic seizures might simply suggest a completed, 
irrevocable, brain injury that predisposes to later epilepsy. 
Given the chronic burden of neurological disability and 
substantial loss of human capacity related to brain injury 
caused by cerebral malaria, neuroprotective clinical trials 
aimed at maintaining normothermia and improved acute 
seizure control are warranted. In previous clinical trials, 
phenobarbital used for aggressive seizure control in 
paediatric cerebral malaria was associated with increased 
mortality probably due to respiratory failure in the 
absence of mechanical ventilatory capacity.41 As such, 
future studies aimed at seizure control should use drugs 
that are less likely to cause respiratory suppression, such 
as levetiracetam. 
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